Archive for the ‘HIV’ Category
Posted by James
The lipodystrophy and metabolic complications that can arise during HAART have not been conclusively associated with one particular drug class or therapeutic agent, although some agents have been implicated more frequently. In fact, in July 2001, the FDA’s Division of Antiviral Drug Products wrote to all manufacturers of antiretroviral drugs and required that they include information on fat redistribution in their package inserts, a warning that had previously been reserved only for the PI class.
Read the rest of this entry »
Posted by James
Resistance to HAART therapy has been a major obstacle in the long-term management of HIV infection. Increasingly, to guide drug selection, clinicians are testing for HIV resistance to antiretroviral agents as well as assessing patients’ detailed drug histories. This testing can use either genotypic or phe-notypic methods to determine whether patients have HIV mutations that confer resistance to currently available medications.
Read the rest of this entry »
Posted by James
Many studies have cited an association between poor adherence and incomplete viral suppression. In one study, 84 patients were assessed after six months of antiretroviral therapy. A significant association was observed between adherence and virological suppression (P < .001). The authors concluded that a high level of adherence to therapy was important for virological success; below 95% compliance, failure rates increased rapidly. This trial suggested that a few missed doses can have a detrimental effect on clinical outcomes.
Read the rest of this entry »
Posted by James
On February 4, 2002, guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, developed by the Panel on Clinical Practices for Treatment of HIV Infection of the Department of Health and Human Services (DHHS), were revised. A panel subcommittee reviews and updates these guidelines each month (see the AIDS Web site).
Read the rest of this entry »
Posted by James
Overview
Although the prevalence of acquired immunodeficiency syndrome (AIDS) in the U.S. continues to rise, there has been a concomitant decrease in AIDS-related morbidity and mortality as a result of advances in antiretroviral therapy. The efficient use of resources is necessary to ensure optimal patient care. To minimize the potential for developing resistance, initial antiretroviral regimens should maximally suppress viral replication.
Read the rest of this entry »
Posted by James
A total of 119 patients were studied. Their mean age was 7.9±5.6 years. Sixty-eight (57.1%) of them were males and 51 (42.9%) were females, giving a male-female ratio of 1.3:1 As shown in Table 1, among 78 patients whose genotype were determined, 49 (62.8%) had hemoglobin genotype AA (HbAA) and 16 (20.5%) had HbSS, while seven (9%) and six (7.7%) had HbAS and HbAC, respectively. My Canadian Order net
Read the rest of this entry »
Posted by James
This study was carried out at the Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria. All pediatric and adolescent patients admitted between January 1996 and December 2002 were identified from the admission records of the orthopedic and pediatric services. These were compared with the central medical records to ensure completeness of identification. All patients with bone and soft tissue infections were then selected. Sociodemographic data as well as data of clinical presentation, genotype, bacterial isolates, and hematological profile were studied. Specimens for bacteriological studies were swabs/aspirates of pus from wounds, sinus, or ulcer. Anaerobic cultures were not done during the study period.
Read the rest of this entry »